For research use only. Not for therapeutic Use.
Amivantamab（Cat No.:I042087）is a bispecific monoclonal antibody designed to target two key receptors involved in cancer cell growth: EGFR (epidermal growth factor receptor) and MET (mesenchymal-epithelial transition factor). By binding to both of these receptors, amivantamab aims to block signaling pathways that drive tumor growth and survival, especially in non-small cell lung cancer (NSCLC) with EGFR mutations or MET amplifications. It is being studied in clinical trials to evaluate its safety, efficacy, and potential as a treatment option, both alone and in combination with other therapies, for various cancers.
| CAS Number | 2171511-58-1 |
| Purity | ≥95% |
